Advances in molecular biology have led to an unprecedented ability to profile the gene-and pathway-level changes that occur in disease [1] [2] [3] [4] . However, most of this information has yet to be exploited in drug development, particularly for drugs that are targeted to patient subpopulations, that reduce the side effects of existing drugs and that provide second-line treatment if drug resistance emerges 5, 6 . One strategy for discovering such drugs is to search existing large chemical libraries [7] [8] [9] [10] [11] [12] [13] for new leads whose activity profiles are similar, but not identical, to those of proven drugs. These compounds may have distinct chemical structures and operate through different mechanisms. The main challenge when using large chemical libraries is how to search them efficiently in ways that scale with the size of the library and the desired number of new drug classes. An efficient approach would be able to classify compounds into different drug classes targeting distinct cellular pathways in a single screening pass.
A r t i c l e s
Advances in molecular biology have led to an unprecedented ability to profile the gene-and pathway-level changes that occur in disease [1] [2] [3] [4] . However, most of this information has yet to be exploited in drug development, particularly for drugs that are targeted to patient subpopulations, that reduce the side effects of existing drugs and that provide second-line treatment if drug resistance emerges 5, 6 . One strategy for discovering such drugs is to search existing large chemical libraries [7] [8] [9] [10] [11] [12] [13] for new leads whose activity profiles are similar, but not identical, to those of proven drugs. These compounds may have distinct chemical structures and operate through different mechanisms. The main challenge when using large chemical libraries is how to search them efficiently in ways that scale with the size of the library and the desired number of new drug classes. An efficient approach would be able to classify compounds into different drug classes targeting distinct cellular pathways in a single screening pass.
Purely computational approaches have been used to perform virtual screens across multiple mechanisms of action 14, 15 , but predictions of chemical mechanism may poorly or nonspecifically predict biological activity (e.g., a predicted kinase inhibitor could affect receptor signaling, cell growth, cytoskeletal structure and many other biological processes). Current biochemical screening approaches 16 are not designed for diversifying the repertoire of compounds within or across cellular processes in a single-pass screen; rather, multiple passes would be required to screen a large compound library, with each pass focused on a different target. Likewise, many current low-dimensional phenotypic screening approaches use readouts that are either too specific (e.g., single target 17 ) or broad (e.g., cell proliferation or death 18 ) to distinguish simultaneously among different mechanistic modes of action in a single-pass screen.
High-content phenotypic screens hold promise for identifying lead compounds across multiple drug classes at a single-pass screen. Multiparametric measures of cellular responses are captured and summarized succinctly as phenotypic (or cytological) profiles 19 or fingerprints 20, 21 and used to group compounds by the similarity of their induced cellular responses. Phenotypic profiles have proven their usefulness in partitioning drug libraries into functional classes and predicting the mechanism of action using guilt by association 19, [22] [23] [24] [25] . However, assay costs for current approaches based on transcriptomics 26, 27 or proteomics [28] [29] [30] are too expensive to be scaled routinely to libraries with tens or hundreds of thousands of compounds 31, 32 .
High-content imaging 13, 19, 25, [33] [34] [35] is an appealing modality due to its relatively lower costs and ability to monitor systems-level responses in individual cells. A key step in every phenotypic screen is the selection of biomarkers (e.g., antibodies, chemical dyes or genetically encoded fluorescent tags). In fluorescent microscopy, only a relatively small number of biomarkers can be monitored simultaneously in each cell. Multiplexing biomarkers and/or performing additional replicate experiments can increase the number of readouts used to probe cellular responses and provide useful information 36, 37 . However, increasing the number of biomarkers can lead to greatly increased costs and time for screening. Notably, there is currently no established strategy for systematically identifying a minimal biomarker set that can accurately classify compounds across multiple, specified drug classes. High-content, image-based screens enable the identification of compounds that induce cellular responses similar to those of known drugs but through different chemical structures or targets. A central challenge in designing phenotypic screens is choosing suitable imaging biomarkers. Here we present a method for systematically identifying optimal reporter cell lines for annotating compound libraries (ORACLs), whose phenotypic profiles most accurately classify a training set of known drugs. We generate a library of fluorescently tagged reporter cell lines, and let analytical criteria determine which among them-the ORACL-best classifies compounds into multiple, diverse drug classes. We demonstrate that an ORACL can functionally annotate large compound libraries across diverse drug classes in a single-pass screen and confirm high prediction accuracy by means of orthogonal, secondary validation assays. Our approach will increase the efficiency, scale and accuracy of phenotypic screens by maximizing their discriminatory power.
The identification of optimal drug classification biomarkers could be addressed for either fixed-or live-cell imaging assays. Fixed-cell assays have the advantage that a wide selection of immunofluorescent (IF) probes are available that can report on the expression or activity of a protein. Additionally, sample preparation and image acquisition steps can be decoupled. On the other hand, live-cell assays avoid timeconsuming fixation steps, costly IF probes and the need to perform replicate experiments across multiple time points.
In our current study, scalability is a central goal; hence, we chose to focus on phenotypic profiling based on live-cell reporters. The key challenge, then, is how to identify reporter cell lines whose phenotypic profiles best enable accurate classification of compounds across diverse drug classes. We address this challenge in three steps (Fig. 1) . First, we construct a library of live-cell reporter cell lines that are fluorescently tagged for genes involved in a wide variety of biological functions. Next, we use analytical criteria to identify the reporter cell line in this library whose phenotypic profiles most accurately classify training drugs across multiple drug classes. (In this study, we focused on cancer-related drug classes.) Finally, we demonstrate that this single reporter cell line, in a single-pass screen, can accurately identify lead compounds across diverse drug classes. We refer to this informative reporter cell line as an ORACL, as classifying compounds into specified drug classes effectively provides functional annotation for a drug library.
RESULTS

Construction of a reporter cell line library for live-cell drug screening
To enable high-content profiling of large-scale compound libraries, we made use of a collection of triply labeled live-cell reporter cell lines (Fig. 2a, left) . The first two labels facilitated automated identification of cellular regions and extraction of information about their morphology. This was established by using a plasmid for cell image segmentation (pSeg; Online Methods), which marked the whole cell (mCherry fluorescent protein (RFP)) and nucleus (histone H2B fused to cyan fluorescent protein (CFP)). The third label allowed each reporter cell line to monitor the expression of a different protein. This was established using central dogma (CD) tagging 38 , a genomic-scale approach for randomly labeling different full-length proteins (marked by inserting yellow fluorescent protein (YFP) as an extra exon). CDtagged proteins are typically expressed at endogenous levels and have preserved functionality, though for our profiling purposes they are only required to serve as reliable biomarkers of cellular responses to compounds.
The collection of reporter cell lines was built from the A549 nonsmall cell lung cancer cell line, which is amenable both to transfection assays (high rates of transfection) and imaging studies (cells do not tend to clump and can be more easily identified by computer). The collection was constructed by selecting a pSeg-tagged parent A549 clone expressing the nuclear and cellular reporters. (Stable pSegtagged A549 clones were grown for tens of passages without signs of reduced expression.) With this clone, ~600 triply-labeled A549 reporter clones were generated. The identities of the CD-tagged genes were identified by 3′ RACE. From this large collection, we selected 93 reporters that were tagged for distinct proteins, placed in diverse Gene Ontology-annotated functional pathways (Fig. 2a, right) , and had YFP levels detectable by microscopy.
As an initial examination of our library of 93 reporter cell lines, we selected six reporter cell lines that represented diverse functional pathways and displayed distinct spatial localization patterns (Supplementary Fig. 1 ). These reporter cell lines were treated for 48 h with six compounds that targeted pathways related to our reporters. Microscopy images revealed that each reporter cell line displayed diverse responses (cell morphology and protein localization) from drug to drug (Supplementary Fig. 1 ). Previous studies with fixedcell assays demonstrated that quantitative measurements of cellular responses can be used to predict targeted cellular pathways for compounds across diverse drug classes 19, 39 . Could our live-cell reporters also be used in a similar fashion? Would compounds from the same (or different) class(es) elicit similar (or dissimilar) responses from our reporter cell lines? Presumably some reporter cell lines will be better than others for making predictions. Could we identify an optimal reporter cell line, whose predictions are highly accurate at classifying compounds into multiple drug classes?
Computation of phenotypic profiles
To address these questions, we made use of phenotypic profiling, an image-informatics approach previously developed for analyzing high-content microscopy screens 19 . Phenotypic profiles effectively transform compounds into vectors whose entries summarize the responses of cells in a population to the perturbation. This transformation occurred in three main steps ( Supplementary Fig. 2 and Online Methods). First, images of perturbed cells were transformed into collections of feature distributions: ~200 features of morphology (e.g., shape of the nuclear and cellular domains) and protein expression 39 (e.g., intensity, localization and texture properties of the tagged protein) are measured for each cell (Supplementary Table 1) . Second, feature distributions for each condition were transformed into numerical scores: for each feature, differences in cumulative distribution functions between perturbed and unperturbed conditions were summarized by a Kolmogorov-Smirnov (KS) statistic 19 . Third, scores were transformed into phenotypic profile vectors: for each perturbation, KS scores were concatenated across features to form a phenotypic profile. The resulting phenotypic profile succinctly summarized the effects of a compound, and could be further extended by concatenating profiles from multiple time points, compound concentrations or even responses from multiple reporter cell lines. We first investigated whether compounds from the same class would produce relatively similar profiles and whether distinct drug classes would result in dissimilar profiles. We treated our six selected reporter cell lines (Supplementary Fig. 1 ) with a small panel of test drugs (31 conditions = 5 compounds × 6 different drug classes + 1 DMSO control; Supplementary Table 2 ) and imaged cellular responses every 12 h for 48 h. 100 DMSO profiles were generated from randomly selecting cells in control conditions (Online Methods). Heat map representations of phenotypic profiles, built by concatenating data across our six reporter cell lines, revealed a strong similarity of compounds from similar drug classes and, likewise, dissimilar profiles for compounds of dissimilar classes (Supplementary Fig. 3) . Thus, as with profiles built from fixed-cell assays and antibody readouts, we observed that profiles based on live-cell readouts produced informative signatures of drug classes.
To select a small number of time points for more scalable screening, we visualized our profiles as time-varying curves by projecting our collection of profiles at each time point into three dimensions. The resulting time traces showed that the unperturbed (DMSO-treated) cells remained in a tight ball ( Supplementary Fig. 4 , gray curves). By contrast, time traces for different classes of drugs moved in different directions away from the DMSO origin, with different members of each class moving in similar directions (Supplementary Fig. 4) . Further, time traces were quite similar across replicate experiments (solid lines vs. dash lines). The divergence of these time traces from one another also suggested that time points of 24 and/or 48 h were sufficient for discriminating among drug classes ( Supplementary  Fig. 5 ). Thus, our results suggested that phenotypic profiles from our reporter cell lines can be used to predict drug classes and that only a small number of time points might be needed for screening.
Identification of the ORACL
To economize large-scale screens, we next investigated to what degree a single reporter cell line and time point could be used to accurately discriminate among our different drug classes. This time we treated all 93 reporter cell lines with our panel of test drugs, imaged cellular responses, and then computed phenotypic profiles for each of the reporter cell lines individually using only the final 48 h time point after drug treatment. As we used only a single time point, each drug profile was a single point in our high-dimensional phenotype space. To assess prediction accuracy, we used a cross-validation approach in which we randomly removed six test drug profiles (one from each of the six classes), computed the centroid of the remaining four drug profiles in each class, and assigned each of the six test profiles to its nearest centroid. Prediction accuracy was determined by repeating this process 100 times and averaging the results across two duplicates of the experiment.
We found that prediction accuracy varied dramatically from reporter to reporter (random guesses from 1 DMSO + 6 drug classes is expected to be ~14% accurate; Fig. 2b , left). As might be expected, the untagged (no CD tag) reporter cell line, labeled only with cellular region markers, displayed the lowest prediction accuracy (~60%). (We note this accuracy is already more than four times better than random guessing, which confirmed recent results that morphology carries considerable information for predicting drug classes 25 .) Nevertheless, our results also confirmed the intuition that additional information from tagged proteins would improve prediction accuracy. The top reporter cell line-tagged with XRCC5, a nuclear-localized protein that functions in DNA double-strand break repair-displayed a high prediction accuracy (94%). This cell line, when compared to others, exhibited more similar phenotypic responses for drugs within the same class (Fig. 2b, (6) Cytoskeleton (14) Apoptosis ( 
Identification of multi-classes hits with ORACL
We next used our ORACL to perform a largescale phenotypic screen of small-molecule compound libraries. These libraries included the National Cancer Institute (NCI) approved oncology drug set IV (101 compounds), the NCI diversity set IV (1,596 compounds), the NCI natural product set III (117 compounds), the Prestwick US Food and Drug Administration-approved drug set (1,100 compounds) and 8,000 compounds from University of Texas Southwestern Medical Center (UTSW 8K set). All compound libraries were assayed at three different concentrations, except the Prestwick and UTSW sets, which were assayed at a single concentration due to their large sizes. Finally, we included our reference drug set. Our reference drug set contained the test drug set used to select the ORACL. Additionally, to test the ability of the ORACL to identify novel drug classes that were not used in its selection, we added a small number of drugs in four new drug classes, for a total of ten drug classes affecting diverse biological processes (Supplementary Table 2 ). All 38 reference drugs were used at eight serial fivefold dilutions. Finally, to increase our chances of identifying compound effects, given the limited number of compound concentrations selected, cells were imaged at both 24 and 48 h (Supplementary Fig. 6 ). In total, profiles were built from ~62,000 three-channel images of ~20,000 conditions (derived from 10,914 compounds and 38 reference drugs at different concentrations as well as control conditions), ~60,000,000 identified cellular regions and ~230 features per cell, yielding a total of ~1.4 × 10 10 data points. Our final compound profiles were built by merging data across the 24-and 48-h time points. As before, these compound profiles can be viewed as points in a high-dimensional feature space. We took a multistep strategy to identify hits. First, we transformed feature space and reduced dimensionality to maximally separate our reference drug classes from one another. Linear discriminant analysis (LDA) 40 was applied to our collection of reference drug profiles to identify an optimal transform that increased separation of profiles across drug classes while decreasing separation of profiles within each class. Second, we assigned our unknown compounds to the nearest reference drug class. A nearest-neighbor approach was applied to the LDA-transformed space to assign each unknown compound to the class of its nearest reference drug. Third, we calculated confidence scores, ranging from 0 (low) to 1 (high), for each prediction. Scores were estimated based on the collection of intra-and interdrug class distances among our reference drug profiles. Compounds were re-annotated as unclassified if their predictions had low confidence scores (a threshold score of 0.1 was heuristically chosen based on calibration with the NCI-approved oncology drug of known mechanism; Supplementary  Fig. 7 and Supplementary Table 3) . Finally, we identified hit compounds. Hits were defined as compounds not annotated by the control class DMSO; that is, hits are bioactive, but may not necessarily be near to known drug classes. Taken together, our approach allowed us to predict which compounds have activity different from DMSO, predict whether they belong to known or novel drug classes, and prioritize compounds for validation based on confidence scores.
Using our strategy, we identified 429 primary hit compounds from our diverse compound libraries ( Fig. 3 and Supplementary Fig. 8 ).
(We note that there is always a tradeoff between favoring precision versus recall for identifying hits in screens. Though favoring recall has the potential advantage of missing fewer candidate compounds, for this study we chose to favor precision to demonstrate the ability of our ORACL to identify high quality-rather than high numbers of-hits in different drug classes.) To filter out primary hits that might have induced weak phenotypes, these 429 primary hits were rescreened (secondary screen) at the highest five concentrations of each reference drug. After this step, 175 high-confidence "secondary hits" remained ( Fig. 3b , middle pie chart), which comprised: 69 unclassified compounds; and 106 compounds classified across 6 of our 10 reference drug classes (49 DNA inhibitors, 45 MT (microtubule) inhibitors, 5 mTOR inhibitors, 4 proteasome inhibitors, 2 histone deacetylase (HDAC) inhibitors, 1 Hsp90 inhibitor; Fig. 3b , bottom pie chart).
Validation of identified hits from the screening
We next investigated the accuracy of our secondary hits. We began with our two smallest predicted classes: Hsp90 and HDACs. Gratifyingly, identified hits in these two classes both had literature support. In the Hsp90 class, the compound NSC330500 (macbecin II) was shown previously to be an Hsp90 inhibitor 41 . In the HDAC class, compounds NSC701852 (from the NCI oncology drug set) and vorinostat (Zolinza; from the Prestwick library) were different names for the same compound (suberoylanilide hydroxamic acid), a known HDAC inhibitor 42 . Proteasome (4) MT (45) Hsp90 (1) HDAC (2) DNA (49) mTOR (5) Unclassified (69 
A r t i c l e s
To test prediction accuracy in our remaining four drug classes, we performed experimental validation (Fig. 4) . We used all of our reference drugs and 175 secondary hits so that we could both calibrate readout thresholds using reference drugs and estimate false-discovery rates for our predictions. Specifically, for each validation, we chose a readout threshold so that 90% of the reference drugs above the threshold belonged to the class to be validated (FDR Ref Fig. 4 top). Then we calculated the false-discovery rate of our secondary hit predictions (FDR hits ) as the percentage of predicted compounds that failed to pass the readout threshold.
To test DNA damaging activity, we carried out immunofluorescence (IF) staining experiments to detect the level of phospho-H2AX, whose level increases rapidly in response to DNA-damaging agents. The DNA-damaging ability of each reference drug/compound was measured by the median of averaged phospho-H2AX intensities in nucleus regions. At the threshold of 60.74 (FDR Ref = 0.1), 76% (37/49) of our predicted DNA compounds (Fig. 4, blue dots) passed the validation (24% failed, FDR hits = 0.24).
To test microtubule-perturbing activity, we carried out live-cell imaging with TUBA1C CD-tagged reporter cell line to examine mitotic arrest. We calculated the mitotic index (the percentage of cells undergoing mitosis) based on cell morphology and tubulin intensity. At the threshold of 0.06 (FDR Ref = 0.1), 96% (43/45) of our predicted MT compounds (Fig. 4, yellow dots) passed the validation (4% failed, FDR hits = 0.04).
To test proteasome-inhibiting activity, we used an ubiquitin-fused R-GFP clone of HeLa cells 43 . Under normal conditions, R-GFP would be degraded through the ubiquitin-proteasome system by the N-end rule pathway, and show no fluorescent intensity. In contrast, proteasome inhibitors cause an increase in R-GFP signal (Fig. 4 , drug PS-341 at bottom). At the threshold of 166 (FDR Ref = 0.1), all our four predicted proteasome hits were validated (Fig. 4, red dots) . Among those, two (carfilzomib/Kyprolis and bortezomib/Velcade) were identified previously in the literature 44, 45 . The other two (NSC26113 and NSC33570) were not previously known as proteasome inhibitors and are new predictions. 
Finally, to test mTOR-inhibiting ability, we chose to measure the level of the phosphorylated ribosomal protein S6 by immunostaining. Under normal conditions, mTOR constitutively phosphorylates the ribosomal protein kinase (S6K), which in turn phosphorylates S6. Therefore, mTOR inhibitors will decrease the level of phosphorylated S6. However, we found that our Hsp90 reference drugs also decreased the phosphorylation level of S6 (Fig. 4) , which was consistent with previous literature 46 . Given that both mTOR and Hsp90 inhibitors reduce the level of phosphorylated S6, we combined these two classes when calculating FDR Ref Fig. 4 , magenta dots) and three predicted mTOR inhibitors (Fig. 4, green  dots) passed the threshold. Two of the three validated mTOR compounds, rapamycin (Rapamune) and everolimus (Afinitor), were previously known in the literature; the other one (NSC176324) is a new prediction.
Taken together, these results suggest that our predictions of drug classes, derived from a single-pass phenotypic screen using our ORACL, had high accuracy across diverse functional classes.
Identification of compounds in novel drug classes
We also tested whether our approach could group compounds in our screen belonging to drug classes that were not included in our reference drugs. We used both an unsupervised and a supervised approach. We first used unsupervised hierarchical clustering to group the secondary screening profiles of all 429 compounds that showed bioactivity (away from DMSO) in our primary phenotypic screen (Fig. 5) . We found 23 significant clusters (P < 0.01, permutation test). As expected, six clusters reflected our initial training classes used to identify our ORACL. Two new clusters were identified because they each grouped together a small number of drugs we had added to our reference set for the primary screen (but were not used for our selection of the ORACL): endoplasmic reticulum (two reference drugs and one unknown) and aurora kinase inhibitors (one reference drug and two unknown). Notably, three of the remaining 15 novel clusters were identified (by literature searches) as: (i) glucocorticoid steroids (26 members, including betamethasone, flunisolide and halcinonide/Halog); (ii) Na + /K + ATPase inhibitors (5 members, including Digoxin, lanatoside C, and proscillaridin); and (iii) dihydrofolate reductase inhibitors (three members, consisting of NSC740 (methotrexate/Otrexup, NCI oncology drug set), NSC382035 (methylbenzoprim, NCI diversity set) and Amethopterin (methotrexate, Prestwick library)).
We next used a supervised approach to perform a virtual screen of the Prestwick and UTSW 8K compound sets. We retrained new classifiers using the original drug set together with two new drug classes (using 15 glucocorticoid compounds and 5 Na + /K + ATPase inhibitors; Supplementary Table 4) that were identified from the previous cluster analysis (dihydrofolate reductase inhibitors were excluded due to their small numbers). Cross-validation showed that our ORACL recalled: 15/15 left-out literature-supported glucocorticoid compounds, and 3/5 Na + /K + ATPase inhibitors (predictions for 2/5 fell below our confidence threshold of 0.1). For our virtual screen, we identified a total of 17 new compounds that were classified into the glucocorticoid class (6 were supported by literature search, 11 had no annotation; Supplementary Table 5 ). These results suggested that our ORACL has the potential to discover compounds in drug classes other than those used for its selection.
DISCUSSION
We address a key challenge of designing phenotypic screens, namely how to select optimal biomarkers. Biomarkers are typically chosen by experts based on prior knowledge or availability of reagents. Here, we took a different approach. Rather than hand-specifying biomarkers that are specific to a single target or pathway, we developed an objective procedure for selecting a maximally informative reporter cell line whose phenotypic profiles are optimized for distinguishing the effects of multiple cancer-drug classes (Fig. 1) . We made use of a diverse collection of reporter cell lines, and let analytical criteria determine which among them-the ORACL-could best classify compounds into multiple, diverse drug classes (Fig. 2) . We then demonstrated that the ORACL's information-rich, high-dimensional phenotypic profiles could be used in a single-pass screen to predict compound leads accurately across multiple drug classes (Figs. 3-5) .
We initially used our ORACL to identify compounds whose activity profiles were similar, but not identical, to current drugs. These new compounds may have similar or distinct chemical structures and operate through different mechanisms (Supplementary Table 6 ). Thus, such an approach provides an opportunity to expand and improve upon classes of drugs that are already known to be effective. Guided by our choice to focus on high-quality (rather high numbers of) hits, we identified 175 compound leads. Our ORACL classified 106 of these into our six reference drug classes. In addition to identifying compounds with DNA (49) and microtubule (45) activity-classes considered low-hanging fruit 47 for drug discoverywe identified mTOR (5), proteasome (4), HDAC (2) and Hsp90 (1) inhibitors. Many of these predictions were subsequently validated through literature or experiment (90/106; Fig. 4) . It is possible that we underestimated the true accuracy of our method. Indeed, our drug classes were defined fairly broadly, and compounds might have activities within a class that would not be detected by our choice of validation assay. For example, to validate DNA compounds we used phospho-H2AX, which reports on DNA double-strand breaks and could miss compounds that affect DNA through alternative mechanisms, such as inhibition of DNA synthesis. Nevertheless, our high overall validation rate of 85% demonstrates that our approach can produce high-quality compound leads across diverse drug classes.
There is no guarantee that an ORACL can identify compounds in classes other than ones for which it was trained. However, for our particular ORACL and compound libraries we were able to identify clusters of unclassified compounds belonging to classes that we did not originally include in the selection of the ORACL, namely glucocorticoids (26), Na + /K + ATPase inhibitors (5) and DHFR inhibitors (3). 
A r t i c l e s
We used these grouping to bootstrap in silico predictions of other unknown compound into these classes. This case study suggested that ORACLs have the potential to identify compounds targeting different cellular pathways that were not included in the original experimental design.
It is not to be expected that a small number of reporter cell lines could be used in a large-scale screen to classify compounds accurately across diverse drug classes. In fact, it is a notable finding that a single reporter cell line could be identified to do so. Our results suggest that the strategy of objectively identifying the right reporter cell lines may be as important as (or at least complement) strategies of increasing the numbers of multiplexed biomarkers 36, 37 .
Our selection of an ORACL was based on an analytical search procedure, which depended on two key sets of inputs. The first set of inputs is the drug training set. How smart a reporter cell line is depends on user-provided definitions of drug classes and choices of specific training drugs in each class (as well as experimental parameters such as chosen doses, treatment times). If a provided training drug class lumps together multiple mechanisms of action (e.g., microtubule stabilizers and destabilizers), then the smart reporter cell lines would be expected to ignore these differences; conversely, if a drug class is broken into more refined subclasses, then the smart reporter cell lines would be expected to distinguish among them. The second set of inputs is the library of reporter cell lines. The more diverse the reporter cell line library, the more likely it is that an ORACL can be identified whose classification accuracy is high enough to be useful for screening. Of course, the success of any reporter cell line (in our or any study) is due to some ineffable combination of cell type, clone, biomarker, cell features (e.g., biomarker expression and cell morphology) and so on. Although a reporter cell line tagged for the biomarker XRCC5 was identified as an ORACL in our study, it is reasonable to expect that for a different study a different reporter cell line, tagged with a different gene and optimized for a different set of perturbations, might be selected as the ORACL. Our study raises the question as to which pathways and readouts are most informative for distinguishing different drug classes, and whether computational approaches, including active learning 48 , could be adapted to predict ORACLs a priori.
The general procedure we describe for finding ORACLs can be incorporated into the design of any phenotypic screen. Desired collections of discovery drug classes can be matched objectively to ORACLs, which will increase the efficiency, scale and accuracy of future phenotypic screens. The identification of ORACLs provides a means to classify very large compound libraries across diverse drug classes. As large chemical libraries become increasingly available, methods that efficiently screen for promising compound leads across multiple drug classes might substantially expand our drug repertoire for diseases such as cancer.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Generation of reporter library. We constructed our live-cell reporter library using the adenocarcinoma cell line A549. As described below, we did this in two steps: (i) we generated a parent clone containing distinct fluorescent labels for cellular regions; (ii) we performed random genomic tagging on this parent clone to build our reporter library.
For visual demarcation of individual cellular and nuclear regions, we constructed a pSeg plasmid (plasmid for image Segmentation), using a combination of standard molecular cloning techniques and Gibson assembly (New England BioLabs, Inc. #E2611), in which a pMYs retrovirus expression vector (Cell Biolabs, Inc. #RTV022 and #RTV023) was modified to express Drosophila histone H2B-fused CFP (Cyan Fluorescent Protein) in the nucleus and mCherry protein in the whole cell. pSeg plasmids were then transfected into the HEK293T-based Platinum-A retroviral packaging cell line (Cell Biolabs, Inc. #RV-102) using Lipofectamine 2000 (Life Technologies #1168027) according to manufacturer's protocol. Retrovirus-containing supernatant was then added to A549 cells for genomic integration. After 2 d of integration at 32 °C, medium was replaced and cells were incubated at 37 °C for 24 h to increase viability. CFP-and mCherry-positive cells were then sorted onto 384-well plate by FACS, and their fluorescence localization was validated by Nikon TE-2000 E2 epifluorescence microscope (Nikon, Inc.). One of the pSeg clones was selected for subsequent generation of our reporter library based on its relative fluorescence intensity and stability compared to other clones.
For random genomic labeling, CD tagging 49 was carried out as in our pSeg labeling step except using a CD tag plasmid (kind gift from Uri Alon). Identification of tagged genes by 3′ RACE was performed as in Sigal et al. (2007) .
Cell lines.
All cell lines have been tested for mycoplasma contamination. The adenocarcinoma cell line A549 was purchased from ATCC; the Ub-R clone of HeLa cells was a kind gift from G. DeMartino.
Cell culture and drug screening assays. A549 adenocarcinoma cells were cultured in RPMI1640 media containing 10% FBS, 2 mM glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin (all from Life Technology, Inc.), at 37 °C, 5% CO 2 and 100% humidity. For screens, cells were grown in 10-cm culture plates overnight, detached by trypsin, counted by TC10 automated cell counter (Bio-Rad Laboratories, Inc.) and seeded onto 384-well plate at a density of 3,000 cells/well by Matrix electronic multichannel pipette (Matrix Technologies Co.). After 24 h at 37 °C, drugs were added by Beckman Coulter BioMek FX liquid handlers (Beckman Coulter, Inc.), and the plate was covered by BreathEasy sealing membrane (Sigma-Adrich, Inc.) and incubated at 37 °C for 2 d.
Drug libraries.
The drug libraries were screened in two batches. Batch 1: the approved oncology drug set IV (101 compounds), the diversity set IV (1,596 compounds), and the natural product set III (117 compounds) (all acquired from NCI). Batch 2: the Prestwick library (1,100 compounds) (purchased from Prestwick Chemical), and the University of Texas Southwestern 8K diversity subset (~8,000 compounds approximating the chemical diversity of the 230K institutional library that was purchased from ChemDiv, ChemBridge, Comgenix, and TimTek). In Batch 1, compounds were screened at three concentrations (10, 1 and 0.1 µM); in Batch 2, compounds were screened at a single concentration (2.5 µM).
Screens.
All experiments below were performed in 384-well plates.
93-reporter data set. 93 different reporters were treated with 30 different drugs spanning 6 drug classes. Plate columns: 23 reporters + 1 control reporter (EIF4A1) were assayed. Plate rows: 15 drugs + DMSO control (row H) (drug positions across drug classes were randomized across plates). Two replicates were performed on different plates. In total, 16 plates were used to generate this data set. (EIF4A1 was included on every plate so that in subsequent analytical steps we could confirm that there were no significant quality control issues, such as plate-to-plate differences or pipetting artifacts.) Screening data set. The XRCC5 reporter was used to screen 10,914 chemical compounds. For all plates, the 2 nd and 23 th columns were treated with only DMSO control and the 1 st and 24 th columns were treated with positive control drug gemcitabine (Gemzar) or PS-341. The rest of each plate (Row A to P, Column 3 to 22) was used for compound screening. There were two types of plates: reference plates, which contained 38 known drugs at eight serial fivefold concentrations used in analytical steps to predict drug classes of unknown chemical compounds; and compound plates, which contained unknown chemical compounds. Our screening was performed in two batches. To avoid normalization issues, we included reference plates in each batch so that profiles and hits could be computed and identified independently. The first batch contained 2 reference plates and 18 compound plates; the second batch contained 5 reference plates and 29 compound plates. The two batches were imaged and analyzed independently.
Validation assays. Secondary assays were performed to validate predictions in drug classes: (i) DNA, (ii) mTOR, (iii) mitosis and (iv) proteasome.
(i), (ii). Immunofluorescence experiments for validation of putative drug mechanisms were carried out in 384-well plates. After 24 h of drug treatment, cells were fixed in 4% PFA in PBS and permeabilized by TBS (20 mM Tris, pH 7.4, and 0.9% NaCl) containing 0.2% Triton X-100. Primary antibodies were incubated overnight at 4 °C in TBS containing 0.1% Triton X-100 and 3% BSA. For validation of DNA inhibitors, phospho-H2A.X antibody (Cat. # 9718, Cell Signaling Tech.) was used in 1:400 dilution. For validation of mTOR inhibitors, phospho-S6 antibody (Cat. #4858, Cell Signaling Tech.) was used in 1:100 dilution. FITC-conjugated secondary antibody (Molecular Probes) was incubated for 2 h at RT together with rhodamine-conjugated phalloidin (Molecular Probes) at appropriate dilutions. At the final washing step, Hoechst 33341 was added to stain DNA.
(iii), (iv). For validation of mitosis inhibitors, live-cell imaging of TUBA1C-CD tag clone of A549 was carried out in a 384-well plate (Sanger sequencing confirmed that TUBA1C was tagged with YFP); images were taken at 3 h, 24 h and 48 h post-drug treatment. For validation of proteasome inhibitors, live-cell imaging of Ub-R clone of HeLa cells 43 (kind gift from G. DeMartino) was carried out in 384-well plate; after 24 h of drug treatment, the medium was exchanged with PBS containing Hoechst 33341 and images were taken.
Image acquisition. Images were acquired by using a Nikon TE-2000 E2 epifluorescence microscope equipped with integrated Perfect-Focus (PFS), Nikon Plan Apochromat 10× objective lens, and CoolSNAP HQ camera (Photometrics) (93-reporter data set) and Zyla 5.5 sCMOS camera (Andor Technology) (Screening data set), using 2×2 camera binning. All image acquisition was controlled by Metamorph software (Universal Imaging). One image was acquired for each well. Images with obvious anomalies (e.g., out of focus, abnormal fluorescent patterns caused by dust, scratches on the plate or fluorescent compounds) were discarded by manual inspection.
Image analysis and feature extraction (all data sets).
In brief, image background subtraction was performed using National Institutes of Health ImageJ Rolling Ball Background Subtraction algorithm 50 . Cells were automatically identified using our in-house watershed-based algorithm 39 , which retrieves nuclear region using nuclear marker then combines cytoplasmic marker to identify cell boundary. 234 features were measured for each identified cell 39 : 30 intensity features, 92 object morphology features, 5 object moment features, 49 Zernike moment features, 26 Haralick texture features and 32 cell morphology features. Most treatment conditions did not induce cell death, and typically more than 1,000 cell objects in each condition were captured and used to build phenotypic profiles. (Interestingly, even for the few compounds in which a fraction of dying or dead cell objects were captured-typically more than 500-these objects still provided useful information for classification.)
Phenotypic profiles. The phenotypic profile of a treatment (compound) was based on the Kolmogorov-Smirnov (KS) statistic 19 . Let F trt,i be the cumulative distribution function (cdf) of feature i and treatment trt, and F ctrl,i be the cdf of feature i of control (DMSO). KS trt,i computes F ctrl,i − F trt,i at the point where |F ctrl,i − F trt,i | attains its maximum. A positive KS roughly indicates a shift of increased feature values compared to DMSO control. Our phenotypic profiles were then simply vectors of all k KS values: P trt = (KS trt,i , …, KS trt,k ) Here, the phenotypic profile of a treatment at a given time point (e.g., 48 h) using one reporter cell line and all features had length 234. We note that all phenotypic profiles were built on a plate-by-plate and time point-by-time point basis, that is, responses from treated wells were only compared to DMSO controls on the same plate at the same time point. We also note that phenotypic profiles can easily be expanded by concatenating profiles from different time points (or from different reporter cell lines).
For the 93-reporter data set (used to select an ORACL), phenotypic profiles were built with features at 48 h. For each 384-well plate in the 93-clone data set, the whole DMSO well of a reporter was used to build F ctrl,i 's when calculating phenotypic profiles of compound treatments. To calculate phenotypic profiles of DMSO, the cell population of the DMSO well was randomly split into two subpopulations, one for building F ctrl,i 's and the other was considered as mock compound treatment to build F trt,i 's. We repeated this procedure 100 times to obtain 100 DMSO phenotypic profiles for each CD-tagged reporter.
For the screening data set, phenotypic profiles were built by concatenating profiles at 24 and 48 h (combining these two time points gives, on average, higher prediction accuracy; Supplementary Fig. 6 ). These resulting compound profiles had length 468 ( = 234 + 234). For each 384-well plate in the screening data set, cells in DMSO wells at I2, J2, K2, L2, M2, N2, O2, P2, A23, B23, C23, D23, E23, F23, G23, H23 were pooled together to build F ctrl,i 's. Other DMSO wells were considered as mock compound treatments to calculate phenotypic profiles for DMSO.
Data visualization (all data sets).
The profile for each compound can be considered as a point embedded in a D-dimensional space (the dimension D is the same as the length of the profile). To visualize the similarity and dissimilarity between compounds, multidimensional scaling (if the number of compounds < 300) or principle component analysis (if the number of compounds ≥300) was performed using Matlab (R2015a) functions mdscale or pca, respectively.
Prediction accuracy of each reporter (93-reporter data set).
To choose a smart reporter, we used prediction accuracy to assess the ability of reporters to discriminate drugs from different drug classes. For each reporter, six drugs (one for each drug class) were randomly chosen to be testing data. The remaining data (24 drugs + 100 DMSO) were used to calculate the centroids of each drug class (including DMSO). Testing data were assigned to the drug class of the nearest centroid. Prediction accuracy was defined as the fraction of correct assignments. The procedure was repeated 100 times to obtain a population of prediction accuracy for each reporter. Mean and s.d. were reported.
Feature selection (screening data set). Our next step was designed to discard unreliable features whose KS scores varied too much from one reference plate to another. We applied linear regression analysis using the reference drugs for each of the two batches of screened libraries independently. If a feature is reproducible, we reasoned that its KS scores from one reference plate should be predictive of the KS scores on another reference plate. For each feature, a linear regression model was fit between data using all 38 reference drugs at the highest four concentrations from two reference plates. For batch 1 we had two replicates of our reference drugs, and features with a coefficient of determination (R 2 ) < 0.8 were discarded; for batch 2 we had five replicates of our references drugs, all ten pairwise coefficients of determination were computed and features that had (R 2 ) < 0.8 for eight or more comparisons were discarded. After feature selection, 8 or 16 were dropped (in batch 1 or 2), leaving 460 or 452 features (respectively) to build our profiles.
Identify effective concentrations of reference drugs (screening data set).
For the reference plates, there were eight serial fivefold dilutions for each drug. Of course, not every concentration had effects on cells and not every drug had the same effective concentration. Therefore, for each drug we identified a concentration above which cells exhibited responses different from DMSO-treated cells. Our strategy was to estimate the range of cellular responses observed in the DMSO treatments, then to search for the lowest drug concentrations that caused phenotypic changes that greatly exceeded this control range. To evaluate the significance of observed cellular responses, we estimated the distribution of control cellular responses to DMSO, {R crt }, (calculating using each DMSO as a treatment and computing µ i and σ i using all other DMSO treatments). Then, for each drug, we chose the effective concentration to be the lowest dose that satisfied the stringent criteria R trt ≥2R*, where R* is the 99% quantile of the collection of control response values {R crt }. For each drug, only the concentrations that were equal or higher than its effective concentration were used to predict drug classes of unknown compounds.
Predict drug classes of unknown compounds by linear discriminant analysis (LDA) and nearest neighbor classification (screening data set). We applied LDA 40, 51 with regularization (shrinkage) 52 to find a projection of feature space that places profiles of reference drugs with the same drug class close to each other but far from profiles of drugs with different drug classes. After the projection was learned using our reference drug profiles, all data (reference drugs and compounds) were projected into the subspace (Supplementary Code).
The distance between a compound and a drug class was then defined to be the shortest distance to any reference drug that belongs to the drug class. Compounds were predicted to belong to the nearest drug class. (This approach is equivalent to prediction based on the drug class of a compound's nearest neighbor in our reference set.) Tenfold cross-validation suggested that the accuracy of this prediction procedure was ~90%.
Confidence (screening data set). We associated each prediction with a confidence value. Intuitively, the greater the distance between a compound and its predicted drug class, the less confident we were of the prediction being correct. Specifically, we defined Unclassified drug class, primary hits and secondary hits (screening data set). Compounds were predicted to be in one of our reference drug classes, which included DMSO. If the associated confidence value was lower than 0.1, we defined the predicted drug class of the compound to be unclassified. We defined primary hits to be compounds that were not predicted as DMSO in the primary screen. Secondary hits were compounds that had the same predicted drug class in the secondary screen as the primary screen for at least one of the concentrations. In total, 175 compounds were identified as secondary hits.
Analysis of narrowing primary to secondary hits. From our 429 primary hits, 175 (41%) had the same predictions in both the primary and secondary screens. The remaining compounds can be separated into three categories: (i) 17 (4%) had bad images; (ii) 78 (18%) showed bioactivity but had inconsistent predictions from the primary screens; and (iii) 159 (37%) became inactive. A main reason why some compounds may have appeared inactive in the secondary screen is that we intentionally removed the lowest three concentrations of reference drugs used in the primary screen to eliminate compounds that induced weak phenotypes close to DMSO. It is also possible that we encountered typical issues such as compounds becoming inactive due to, for example, multiple freeze/thaw cycles.
Benchmark of our prediction using NCI oncology drug set. The NCI oncology library contains 101 well-characterized drugs. We analyzed the results of npg our primary screen for this library and offer the following rationale for our hit/non-hit calls.
1. Quality control. 3/101 drugs had bad images (out-of-focus or artifact fluorescent patterns), leaving 98 drugs for subsequent analysis.
2. Hits. 50/98 drugs were identified as hits (bioactive compounds): 42 with classified predictions (83% accuracy) and 8 as unclassified (the majority of which belong to classes that were not included in our reference drugs, such as RTK inhibitors, ALK inhibitors, and histamine N-methyltransferase inhibitors).
3. Non-hits. 48/98 were identified as non-hits. We identified three main reasons for these being non-hits. (i) Resistance. Our reporter cell line (derived from A549) has been reported to be resistant to several non-hit drugs in this library, including Cisplatin 53 , gefitinib (Iressa) 54 and erlotinib (Tarceva) 55 .
(ii) Biological relevance. Some non-hit drugs may act through mechanisms that are irrelevant to the biology of our particular non-small cell lung cancerderived reporter cell line, such as, imiquimod (Aldara), used as an immune response modifier; zoledronic acid (Zometa), used to slow down bone resorption; and exemestane (Aromasin), used to inhibit aromatase, which synthesizes estrogen. (iii) Dose. An issue for all large-scale drug screens is dose. Our screen was no exception, and in several cases chosen concentrations were insufficient to elicit a response that differed from control (DMSO). For example, oxaliplatin (Eloxatin) was screened in the NCI oncology library at 10, 1 and 0.1 µM, which is below the minimal concentration (25 µM) we found was needed to induce a strong non-DMSO response in our reference drug set, and thus was deemed a non-hit. A similar situation occurred for Pemetrexed.
Readouts of validation experiments.
For DNA validation experiments, the effect of a compound was measured by the median of the average nucleus phosphorylated H2AX intensity of all cells in the well. For mTOR validation experiments, the effect of a compound was measured by the negative log of the median of the average cytoplamic pS6 intensity of all cells in the well. For proteasome validation experiments, the effect of a compound was measured by the mean of the average nucleus GFP intensity of all cells in the well. For MT validation experiments, a mitotic index (the proportion of cells undergoing mitosis) was calculated for each compound. A mitotic cell was required to meet each of the following (empirically determined) criteria: Cell solidity > 0.95 (convex shape), cell eccentricity < 0.6 (close to a circle), nucleus solidity > 0.95, nucleus eccentricity < 0.6, median of cytoplasmic mCherry intensity > 800 (living cells), and total TUBA1C intensity > 75,000.
False-discovery rate (FDR) in validation experiments. We adopted a twostep strategy to evaluate the quality of our predictions. First, we used the ground truth reference drugs to calibrate readout thresholds for each drug class to be validated (DNA, MT, Proteasome or mTOR). In particular, we computed FDR Ref as a function of readout threshold for each validation experiment. Here, FDR Ref was defined to be the percentage of ground truth reference drugs that were not in this drug class out of all reference drugs that passed the chosen threshold. In Figure 4 , all thresholds were chosen to give a 0.1 FDR Ref .
Second, we evaluated the quality of our prediction procedure on our secondary hits based on chosen readout thresholds. Define: true negatives (positives) to be compounds that were not (were) predicted to be in a drug class that fell below (above) our validation threshold; and false negatives (positives) to be compounds that that were not (were) predicted to be in an drug class but fell above (below) our validation threshold. (We abbreviate these as TN, TP, FN and FP as per usual convention.) We then defined FDR = FP/(TP + FP.)
As an example, 49 DNA compounds were originally predicted. We then tested all 175 secondary hits for disruption of DNA activity. Based on calibration with our reference data set, a threshold of 60.74 for phosphorylated H2AX staining gave 0.1 FDR Ref . Based on that threshold, 12 of 49 predicted DNA compounds were below the threshold (FP = 12, TP = 37); we therefore computed an FDR of 0.24 (12/49) .
Hierarchical clustering and cluster assignment. To identify novel drug classes, we performed the average linkage hierarchical clustering. We made use of the pair-wise distances between our reference drugs to decide the threshold for cluster assignment. We first separated the pair-wise distances between our reference drugs into two groups: within-class distance and between-class distance. Then we fitted a logistic regression model and chose the threshold to be the distance at which the probability of being within-class distance equals the probability of being between-class distance. This threshold was used as the cutoff for the hierarchical clustering tree to determine clusters. A standard permutation test (randomization of cluster labels implemented in Matlab 2015a) was used to evaluate the significance of clusters.
Supervised approach to assess the ability of our ORACL to identify novel drug classes. From our hierarchical clustering of the 429 hit compounds, 15/26 compounds in the glucocorticoid class and 5/5 compounds in Na + /K + ATPase inhibitors had literature support for their function. These compounds were then added as new reference drugs (Supplementary Table 4) to the original set of ten reference drug classes. We used a fivefold cross-validation strategy to evaluate both the recall and the ability to identify new compounds within the Prestwick and UTSW 8K libraries. In each iteration, we randomly selected a subset of the new reference drugs (12/15 literature supported compounds in the glucocorticoid class, and 4/5 in the Na + /K + ATPase inhibitor class) and re-preformed the whole prediction process (which resulted in new combinations of cell phenotype features for each in silico screen). To evaluate recall, we evaluated our ability to re-identify compounds left out in each iteration of cross validation (3 for glucocorticoid class and 1 for Na + /K + ATPase inhibitors; Supplementary Table 5) . To evaluate the ability to identify new compound candidates, we pulled out all compounds that were classified into these two new drug classes (Supplementary Table 5 ; blue text: compounds contained in our original 429 hits; yellow highlight: literature-supported predictions; all others: novel hits from the in silico screen not contained in our original 429 hits).
